There has been another twist in the Crispr-Cas9 patent saga. The US Court of Appeals for the Federal Circuit in May 2025 ruled that the US Patent Trial and Appeal Board (PTAB) had been mistaken in its earlier decision in favouring the Broad Institute for inventing the gene editing tool.